PDF(Pubmed)
Abstract：
UNASSIGNED: Decision-making is a complex process, and most studies showed that patients with mild cognitive impairment (MCI) make worse decisions than healthy people.
UNASSIGNED: This study aims to evaluate the effect of rivastigmine on the decision-making of MCI patients using the Cambridge Neuropsychological Test Automated Battery (CANTAB) tests.
UNASSIGNED: The study was conducted at the Roozbeh Hospital neurology clinic, and 30 patients with mild cognitive impairment over 40 years old were randomly recruited to receive rivastigmine or placebo twice daily for 12 weeks. The initial dose of rivastigmine or placebo was 1.5 mg twice daily and was increased to 3 mg twice daily per patient compliance. A CANTAB test was conducted before and following the intervention.
UNASSIGNED: The mean age of patients in the rivastigmine group was 58.93 ± 10.88, and in the placebo group was 59.33 ± 10.34. The median MMSE (Mini-Mental State Examination) was 26 (IQR = 25 - 26) in both groups. Patients in the rivastigmine group showed significant differences in all subgroup tests of CGT, IST, and SST except in risk adjustment in the CGT test, discrimination in the IST test, and median correct RT on the go trial and SSRT in the SST test. The most commonly reported adverse effects were gastrointestinal complications.
UNASSIGNED: According to the results, rivastigmine significantly improved the primary decision-making outcomes in comparison with placebo.
UNASSIGNED: This study aims to evaluate the effect of rivastigmine on the decision-making of MCI patients using the Cambridge Neuropsychological Test Automated Battery (CANTAB) tests.
UNASSIGNED: The study was conducted at the Roozbeh Hospital neurology clinic, and 30 patients with mild cognitive impairment over 40 years old were randomly recruited to receive rivastigmine or placebo twice daily for 12 weeks. The initial dose of rivastigmine or placebo was 1.5 mg twice daily and was increased to 3 mg twice daily per patient compliance. A CANTAB test was conducted before and following the intervention.
UNASSIGNED: The mean age of patients in the rivastigmine group was 58.93 ± 10.88, and in the placebo group was 59.33 ± 10.34. The median MMSE (Mini-Mental State Examination) was 26 (IQR = 25 - 26) in both groups. Patients in the rivastigmine group showed significant differences in all subgroup tests of CGT, IST, and SST except in risk adjustment in the CGT test, discrimination in the IST test, and median correct RT on the go trial and SSRT in the SST test. The most commonly reported adverse effects were gastrointestinal complications.
UNASSIGNED: According to the results, rivastigmine significantly improved the primary decision-making outcomes in comparison with placebo.
摘要：
■决策是一个复杂的过程，大多数研究表明，轻度认知障碍（MCI）患者比健康人做出更糟糕的决定。
■本研究旨在使用剑桥神经心理学测试自动电池（CANTAB）测试评估卡巴拉汀对MCI患者决策的影响。
这项研究是在Roozbeh医院神经科诊所进行的，30例年龄超过40岁的轻度认知障碍患者被随机招募接受卡巴拉汀或安慰剂，每天两次，持续12周。卡巴拉汀或安慰剂的初始剂量为1.5mg，每天2次，增加至3mg，每天2次。在干预前后进行CANTAB测试。
■利伐斯的明组患者的平均年龄为58.93±10.88，安慰剂组为59.33±10.34。两组的MMSE（简易精神状态检查）中位数为26（IQR=25-26）。利伐斯的明组的患者在CGT的所有亚组测试中显示出显著差异，IST,和SST，除了CGT测试中的风险调整之外，IST测试中的歧视，以及在进行试验中的中位正确RT和SST检验中的SSRT。最常见的不良反应是胃肠道并发症。
■根据结果，与安慰剂相比,利伐斯的明显著改善了主要决策结果.
■本研究旨在使用剑桥神经心理学测试自动电池（CANTAB）测试评估卡巴拉汀对MCI患者决策的影响。
这项研究是在Roozbeh医院神经科诊所进行的，30例年龄超过40岁的轻度认知障碍患者被随机招募接受卡巴拉汀或安慰剂，每天两次，持续12周。卡巴拉汀或安慰剂的初始剂量为1.5mg，每天2次，增加至3mg，每天2次。在干预前后进行CANTAB测试。
■利伐斯的明组患者的平均年龄为58.93±10.88，安慰剂组为59.33±10.34。两组的MMSE（简易精神状态检查）中位数为26（IQR=25-26）。利伐斯的明组的患者在CGT的所有亚组测试中显示出显著差异，IST,和SST，除了CGT测试中的风险调整之外，IST测试中的歧视，以及在进行试验中的中位正确RT和SST检验中的SSRT。最常见的不良反应是胃肠道并发症。
■根据结果，与安慰剂相比,利伐斯的明显著改善了主要决策结果.
